Jefferies analyst Eun K. Yang, Ph.D trimmed his price target on Buy-rated Opko Health (NYSE: OPK) to $10.50 (from $11.00) following Q2 results but maintained a Buy rating.

Yang commented, "Narrower 2Q14 net loss of $25.5M (vs. ours of $31.8M) primarily on lower OpEx; end-2Q14 cash of ~$134M enough into 2H15. As expected, first Ph3 for Rayaldee was positive (no detailed data yet); with several generic vitamin D2 analogs for SHPT (Chart 1), our prior nephrologists discussions indicated a high bar for new entrants such as Rayaldee."

The firm bumped FY 2014 EPS from ($0.35) to ($0.30) and maintained FY 2015 AT ($0.24).

For an analyst ratings summary and ratings history on Opko Health click here. For more ratings news on Opko Health click here.

Shares of Opko Health closed at $9.08 yesterday.